Editas Medicine, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Editas Medicine, Inc. on January 10, 2020, regarding events occurring on January 9, 2020. The filing discloses a significant change in executive leadership within the finance department.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
On January 9, 2020, the Board of Directors appointed Michelle Robertson as Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer, Treasurer, and Assistant Secretary, effective immediately. She succeeded Eric Ek, whose tenure as interim Chief Financial Officer and related roles concluded upon her appointment.
Management Commentary and Compensation Details
Ms. Robertson's employment agreement, dated December 3, 2019, includes the following compensation terms:
- Base Salary: $400,000 annually.
- Target Bonus: 40% of base salary.
- Sign-on Bonus: $140,000 (subject to repayment if employment ends within the first year for cause or without good reason).
- Stock Options: 120,000 shares with an exercise price of $30.65 per share. Vesting begins 25% on January 9, 2021, followed by monthly vesting of 2.0833% until January 9, 2024.
- Restricted Stock Units (RSUs): 20,000 shares vesting 25% annually on each anniversary of January 9, 2020, through January 9, 2024.
Ms. Robertson brings prior experience as CFO of Momenta Pharmaceuticals, Inc., and held finance leadership roles at Baxalta, Ironwood Pharmaceuticals, and Genzyme.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 120,000 stock options granted to the new CFO.
- Confirm the terms of the Severance Benefits Plan referenced for the sign-on bonus repayment and potential severance.
- Review the company's cash position to assess the impact of the $140,000 sign-on bonus and future equity dilution.
- Monitor future filings for the departure of Eric Ek and any transition details not covered in this report.